English

TherapeuticsMD, Inc.

EDGAR

TXMD Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2024: about USD 1.761M, using the latest reported figures. The previous period, 2023, was about USD 1.302M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

724 thousand USD

2026 Q1 · USD

Exact inputs and evidence

Revenue: 724000 USD Source

Operating cash flow

944 thousand USD

2026 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: 944000 USD Source

Cash and cash equivalents: 5.75 million USD 2025-03-31 Source
Exact value

5745000 USD
Long-term debt including current maturities: 93.6 million USD 2022-09-30 Source
Exact value

93602000 USD
Shares outstanding: 11.6 million uref_2124171756 2026-06-30 Source
Exact value

11574000 uref_2124171756

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

2.7 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: 1080000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 699000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: 2079000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 1080000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 2454000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 2079000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 944000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2024-12-31
Operating income: 11 of 11 periods available· newest 2024-12-31
Net income: 11 of 11 periods available· newest 2024-12-31
Operating cash flow: 11 of 11 periods available· newest 2024-12-31
Capital expenditure: 8 of 11 periods available· newest 2021-12-31
Total assets: 11 of 11 periods available· newest 2024-12-31
Total liabilities: 10 of 11 periods available· newest 2024-12-31
Current assets: 11 of 11 periods available· newest 2024-12-31
Current liabilities: 11 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2021-12-31
Shares outstanding: 11 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+35.3%

Prior period

USD 1.3 million

2023-01-01 – 2023-12-31
Current period

USD 1.76 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

1761000 − 1302000 = 459000 USD

1302000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
1761000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TherapeuticsMD, Inc. · 2024-12-31 TherapeuticsMD, Inc. (edgar:25743) Year-over-year change in Revenue: 459000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1761000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/ea0232034-10k_therapeu.htm#730912 Filing: 000101376225003442 Input fundies:Revenue: 1302000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/ea0232034-10k_therapeu.htm#731623 Filing: 000101376225003442
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 8.1 million

Prior period

−USD 10.28 million

2023-01-01 – 2023-12-31
Current period

−USD 2.18 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-2181000 − -10278000 = 8097000 USD

-10278000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-2181000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TherapeuticsMD, Inc. · 2024-12-31 TherapeuticsMD, Inc. (edgar:25743) Year-over-year change in Net income: 8097000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2181000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/ea0275992-10ka1_therap.htm#1160078 Filing: 000121390026037918 Input fundies:NetIncome: -10278000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/ea0232034-10k_therapeu.htm#1244248 Filing: 000101376225003442
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 24.25 million

Prior period

−USD 23.08 million

2023-01-01 – 2023-12-31
Current period

USD 1.17 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

1170000 − -23081000 = 24251000 USD

-23081000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
1170000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TherapeuticsMD, Inc. · 2024-12-31 TherapeuticsMD, Inc. (edgar:25743) Year-over-year change in Operating cash flow: 24251000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 1170000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/ea0275992-10ka1_therap.htm#831445 Filing: 000121390026037918 Input fundies:OperatingCashFlow: -23081000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/ea0232034-10k_therapeu.htm#827527 Filing: 000101376225003442
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 1.76 million 100% of revenue
Operating costs Derived USD 7.87 million 447% of revenue
Operating income −USD 6.11 million −347% of revenue
Tax, interest and other Derived −USD 3.93 million −223% of revenue
Net income −USD 2.18 million −124% of revenue

Cash

Operating cash flow USD 1.17 million 66% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 523% of revenue.
2016 Operating loss: operating costs were 566% of revenue.
2017 Operating loss: operating costs were 563% of revenue.
2018 Operating loss: operating costs were 909% of revenue.
2019 Operating loss: operating costs were 405% of revenue.
2020 Operating loss: operating costs were 340% of revenue.
2021 Operating loss: operating costs were 3,193% of revenue.
2022 Net income was higher than operating income, so the split is not drawn.
2023 Operating loss: operating costs were 755% of revenue.
2024 Operating loss: operating costs were 447% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	20142898	105333083 Derived	-85190185	-113161 Derived	-85077024	-79209376 Derived	Source 2015-01-01 – 2015-12-31: 20142898 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -85190185 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -85077024 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -79044119 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 165257 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	19356450	109610050 Derived	-90253600	-378141 Derived	-89875459	-69538487 Derived	Source 2016-01-01 – 2016-12-31: 19356450 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -90253600 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -89875459 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -69142333 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 396154 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	16777713	94406423 Derived	-77628710	-703330 Derived	-76925380	-76217431 Derived	Source 2017-01-01 – 2017-12-31: 16777713 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -77628710 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -76925380 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -76155614 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 61817 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	16099460	146319630 Derived	-130220170	2396990 Derived	-132617160	-107028821 Derived	Source 2018-01-01 – 2018-12-31: 16099460 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -130220170 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -132617160 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -106811781 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 217040 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	49647000	200852000 Derived	-151205000	24940000 Derived	-176145000	-168168000 Derived	Source 2019-01-01 – 2019-12-31: 49647000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -151205000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -176145000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -165718000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2450000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	64872000	220413000 Derived	-155541000	27983000 Derived	-183524000	-159678000 Derived	Source 2020-01-01 – 2020-12-31: 64872000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -155541000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -183524000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -159471000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 207000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	2573000	82150000 Derived	-79577000	92838000 Derived	-172415000	-55167000 Derived	Source 2021-01-01 – 2021-12-31: 2573000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -79577000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -172415000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -55133000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 34000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	69963000	68772000 Derived	1191000	-110806000 Derived	111997000	Unavailable	Source 2022-01-01 – 2022-12-31: 69963000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 1191000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 111997000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 9359000 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	1302000	9825000 Derived	-8523000	1755000 Derived	-10278000	Unavailable	Source 2023-01-01 – 2023-12-31: 1302000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -8523000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -10278000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -23081000 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	1761000	7873000 Derived	-6112000	-3931000 Derived	-2181000	Unavailable	Source 2024-01-01 – 2024-12-31: 1761000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -6112000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -2181000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 1170000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.8M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	20142898	Revenue: 20142898 Open source
20162016-12-31	Revenue	19356450	Revenue: 19356450 Open source
20172017-12-31	Revenue	16777713	Revenue: 16777713 Open source
20182018-12-31	Revenue	16099460	Revenue: 16099460 Open source
20192019-12-31	Revenue	49647000	Revenue: 49647000 Open source
20202020-12-31	Revenue	64872000	Revenue: 64872000 Open source
20212021-12-31	Revenue	2573000	Revenue: 2573000 Open source
20222022-12-31	Revenue	69963000	Revenue: 69963000 Open source
20232023-12-31	Revenue	1302000	Revenue: 1302000 Open source
20242024-12-31	Revenue	1761000	Revenue: 1761000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

35.3% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	34.1%	Revenue: 20142898 Open source Revenue: 15026219 Open source
20162016-12-31	Year over year	-3.9%	Revenue: 19356450 Open source Revenue: 20142898 Open source
20172017-12-31	Year over year	-13.3%	Revenue: 16777713 Open source Revenue: 19356450 Open source
20182018-12-31	Year over year	-4%	Revenue: 16099460 Open source Revenue: 16777713 Open source
20192019-12-31	Year over year	208.4%	Revenue: 49647000 Open source Revenue: 16099460 Open source
20202020-12-31	Year over year	30.7%	Revenue: 64872000 Open source Revenue: 49647000 Open source
20212021-12-31	Year over year	-96%	Revenue: 2573000 Open source Revenue: 64872000 Open source
20222022-12-31	Year over year	2,619.1%	Revenue: 69963000 Open source Revenue: 2573000 Open source
20232023-12-31	Year over year	-98.1%	Revenue: 1302000 Open source Revenue: 69963000 Open source
20242024-12-31	Year over year	35.3%	Revenue: 1761000 Open source Revenue: 1302000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -347.1% 2024

Net margin -123.9% 2024

Free cash flow margin -2,144.1% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-422.9%	Operating Income: -85190185 Open source Revenue: 20142898 Open source
20162016-12-31	Operating margin	-466.3%	Operating Income: -90253600 Open source Revenue: 19356450 Open source
20172017-12-31	Operating margin	-462.7%	Operating Income: -77628710 Open source Revenue: 16777713 Open source
20182018-12-31	Operating margin	-808.8%	Operating Income: -130220170 Open source Revenue: 16099460 Open source
20192019-12-31	Operating margin	-304.6%	Operating Income: -151205000 Open source Revenue: 49647000 Open source
20202020-12-31	Operating margin	-239.8%	Operating Income: -155541000 Open source Revenue: 64872000 Open source
20212021-12-31	Operating margin	-3,092.8%	Operating Income: -79577000 Open source Revenue: 2573000 Open source
20222022-12-31	Operating margin	1.7%	Operating Income: 1191000 Open source Revenue: 69963000 Open source
20232023-12-31	Operating margin	-654.6%	Operating Income: -8523000 Open source Revenue: 1302000 Open source
20242024-12-31	Operating margin	-347.1%	Operating Income: -6112000 Open source Revenue: 1761000 Open source
20152015-12-31	Net margin	-422.4%	Net Income: -85077024 Open source Revenue: 20142898 Open source
20162016-12-31	Net margin	-464.3%	Net Income: -89875459 Open source Revenue: 19356450 Open source
20172017-12-31	Net margin	-458.5%	Net Income: -76925380 Open source Revenue: 16777713 Open source
20182018-12-31	Net margin	-823.7%	Net Income: -132617160 Open source Revenue: 16099460 Open source
20192019-12-31	Net margin	-354.8%	Net Income: -176145000 Open source Revenue: 49647000 Open source
20202020-12-31	Net margin	-282.9%	Net Income: -183524000 Open source Revenue: 64872000 Open source
20212021-12-31	Net margin	-6,700.9%	Net Income: -172415000 Open source Revenue: 2573000 Open source
20222022-12-31	Net margin	160.1%	Net Income: 111997000 Open source Revenue: 69963000 Open source
20232023-12-31	Net margin	-789.4%	Net Income: -10278000 Open source Revenue: 1302000 Open source
20242024-12-31	Net margin	-123.9%	Net Income: -2181000 Open source Revenue: 1761000 Open source
20152015-12-31	Free cash flow margin	-393.2%	Revenue: 20142898 Open source Operating Cash Flow: -79044119 Open source Capital Expenditure: 165257 Open source
20162016-12-31	Free cash flow margin	-359.3%	Revenue: 19356450 Open source Operating Cash Flow: -69142333 Open source Capital Expenditure: 396154 Open source
20172017-12-31	Free cash flow margin	-454.3%	Revenue: 16777713 Open source Operating Cash Flow: -76155614 Open source Capital Expenditure: 61817 Open source
20182018-12-31	Free cash flow margin	-664.8%	Revenue: 16099460 Open source Operating Cash Flow: -106811781 Open source Capital Expenditure: 217040 Open source
20192019-12-31	Free cash flow margin	-338.7%	Revenue: 49647000 Open source Operating Cash Flow: -165718000 Open source Capital Expenditure: 2450000 Open source
20202020-12-31	Free cash flow margin	-246.1%	Revenue: 64872000 Open source Operating Cash Flow: -159471000 Open source Capital Expenditure: 207000 Open source
20212021-12-31	Free cash flow margin	-2,144.1%	Revenue: 2573000 Open source Operating Cash Flow: -55133000 Open source Capital Expenditure: 34000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 69963000 Open source Operating Cash Flow: 9359000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 1302000 Open source Operating Cash Flow: -23081000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 1761000 Open source Operating Cash Flow: 1170000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 1.2M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	-79044119	Operating Cash Flow: -79044119 Open source
20162016-12-31	Operating cash flow	-69142333	Operating Cash Flow: -69142333 Open source
20172017-12-31	Operating cash flow	-76155614	Operating Cash Flow: -76155614 Open source
20182018-12-31	Operating cash flow	-106811781	Operating Cash Flow: -106811781 Open source
20192019-12-31	Operating cash flow	-165718000	Operating Cash Flow: -165718000 Open source
20202020-12-31	Operating cash flow	-159471000	Operating Cash Flow: -159471000 Open source
20212021-12-31	Operating cash flow	-55133000	Operating Cash Flow: -55133000 Open source
20222022-12-31	Operating cash flow	9359000	Operating Cash Flow: 9359000 Open source
20232023-12-31	Operating cash flow	-23081000	Operating Cash Flow: -23081000 Open source
20242024-12-31	Operating cash flow	1170000	Operating Cash Flow: 1170000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -55.2M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	-79209376	Operating Cash Flow: -79044119 Open source Capital Expenditure: 165257 Open source
20162016-12-31	Free cash flow	-69538487	Operating Cash Flow: -69142333 Open source Capital Expenditure: 396154 Open source
20172017-12-31	Free cash flow	-76217431	Operating Cash Flow: -76155614 Open source Capital Expenditure: 61817 Open source
20182018-12-31	Free cash flow	-107028821	Operating Cash Flow: -106811781 Open source Capital Expenditure: 217040 Open source
20192019-12-31	Free cash flow	-168168000	Operating Cash Flow: -165718000 Open source Capital Expenditure: 2450000 Open source
20202020-12-31	Free cash flow	-159678000	Operating Cash Flow: -159471000 Open source Capital Expenditure: 207000 Open source
20212021-12-31	Free cash flow	-55167000	Operating Cash Flow: -55133000 Open source Capital Expenditure: 34000 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: 9359000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -23081000 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: 1170000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

29.5% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	14.5%	Total Liabilities: 10665700 Open source Total Assets: 73728846 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 142472020 Open source
20172017-12-31	Liabilities / assets	9.3%	Total Liabilities: 13321195 Open source Total Assets: 143229910 Open source
20182018-12-31	Liabilities / assets	54%	Total Liabilities: 114459803 Open source Total Assets: 211983924 Open source
20192019-12-31	Liabilities / assets	96.5%	Total Liabilities: 256784517 Open source Total Assets: 265985637 Open source
20202020-12-31	Liabilities / assets	168.3%	Total Liabilities: 305611000 Open source Total Assets: 181610000 Open source
20212021-12-31	Liabilities / assets	155.2%	Total Liabilities: 263093000 Open source Total Assets: 169472000 Open source
20222022-12-31	Liabilities / assets	61.1%	Total Liabilities: 55315000 Open source Total Assets: 90458000 Open source
20232023-12-31	Liabilities / assets	32.4%	Total Liabilities: 14022000 Open source Total Assets: 43309000 Open source
20242024-12-31	Liabilities / assets	29.5%	Total Liabilities: 11452000 Open source Total Assets: 38822000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.37× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	6.63×	Current Assets: 70680120 Open source Current Liabilities: 10665700 Open source
20162016-12-31	Current assets / current liabilities	9.3×	Current Assets: 139410173 Open source Current Liabilities: 14982599 Open source
20172017-12-31	Current assets / current liabilities	10.48×	Current Assets: 139554072 Open source Current Liabilities: 13321195 Open source
20182018-12-31	Current assets / current liabilities	4.55×	Current Assets: 186779261 Open source Current Liabilities: 41078789 Open source
20192019-12-31	Current assets / current liabilities	3.93×	Current Assets: 208416180 Open source Current Liabilities: 53004825 Open source
20202020-12-31	Current assets / current liabilities	2.17×	Current Assets: 128404000 Open source Current Liabilities: 59238000 Open source
20212021-12-31	Current assets / current liabilities	0.47×	Current Assets: 119468000 Open source Current Liabilities: 252891000 Open source
20222022-12-31	Current assets / current liabilities	1.18×	Current Assets: 55351000 Open source Current Liabilities: 46839000 Open source
20232023-12-31	Current assets / current liabilities	1.72×	Current Assets: 11796000 Open source Current Liabilities: 6854000 Open source
20242024-12-31	Current assets / current liabilities	2.37×	Current Assets: 12259000 Open source Current Liabilities: 5166000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 85.08 million Exact value Exact value: -85077024 USD 2015-01-01 – 2015-12-31: -85077024 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2015-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -85077024 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -85077024 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713118000776/txmd-20171231.xml#196633 Filing: 000138713118000776 The citation records this snapshot. The page link may show a newer release later.	−USD 79.04 million Exact value Exact value: -79044119 USD 2015-01-01 – 2015-12-31: -79044119 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2015-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -79044119 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -79044119 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713118000776/txmd-20171231.xml#201733 Filing: 000138713118000776 The citation records this snapshot. The page link may show a newer release later.	USD 165,257 Exact value Exact value: 165257 USD 2015-01-01 – 2015-12-31: 165257 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2015-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 165257 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 165257 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713118000776/txmd-20171231.xml#202779 Filing: 000138713118000776 The citation records this snapshot. The page link may show a newer release later.	−USD 79.21 million Calculation and evidence -79044119 − 165257 USD Exact free cash flow: -79209376 USD 2015-01-01 – 2015-12-31: -79044119 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 165257 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2015-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -79209376 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -79044119 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713118000776/txmd-20171231.xml#201733 Filing: 000138713118000776 Input fundies:CapitalExpenditure: 165257 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713118000776/txmd-20171231.xml#202779 Filing: 000138713118000776 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 89.88 million Exact value Exact value: -89875459 USD 2016-01-01 – 2016-12-31: -89875459 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2016-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -89875459 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89875459 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713119001471/txmd-20181231.xml#157061 Filing: 000138713119001471 The citation records this snapshot. The page link may show a newer release later.	−USD 69.14 million Exact value Exact value: -69142333 USD 2016-01-01 – 2016-12-31: -69142333 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2016-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -69142333 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69142333 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713119001471/txmd-20181231.xml#737278 Filing: 000138713119001471 The citation records this snapshot. The page link may show a newer release later.	USD 396,154 Exact value Exact value: 396154 USD 2016-01-01 – 2016-12-31: 396154 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2016-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 396154 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 396154 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713119001471/txmd-20181231.xml#738494 Filing: 000138713119001471 The citation records this snapshot. The page link may show a newer release later.	−USD 69.54 million Calculation and evidence -69142333 − 396154 USD Exact free cash flow: -69538487 USD 2016-01-01 – 2016-12-31: -69142333 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 396154 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2016-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -69538487 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69142333 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713119001471/txmd-20181231.xml#737278 Filing: 000138713119001471 Input fundies:CapitalExpenditure: 396154 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713119001471/txmd-20181231.xml#738494 Filing: 000138713119001471 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 76.93 million Exact value Exact value: -76925380 USD 2017-01-01 – 2017-12-31: -76925380 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2017-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -76925380 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -76925380 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/txmd-10k_123119.htm#1471293 Filing: 000138713120002086 The citation records this snapshot. The page link may show a newer release later.	−USD 76.16 million Exact value Exact value: -76155614 USD 2017-01-01 – 2017-12-31: -76155614 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2017-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -76155614 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76155614 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/txmd-10k_123119.htm#1514893 Filing: 000138713120002086 The citation records this snapshot. The page link may show a newer release later.	USD 61,817 Exact value Exact value: 61817 USD 2017-01-01 – 2017-12-31: 61817 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2017-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 61817 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 61817 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/txmd-10k_123119.htm#1526030 Filing: 000138713120002086 The citation records this snapshot. The page link may show a newer release later.	−USD 76.22 million Calculation and evidence -76155614 − 61817 USD Exact free cash flow: -76217431 USD 2017-01-01 – 2017-12-31: -76155614 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 61817 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2017-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -76217431 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76155614 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/txmd-10k_123119.htm#1514893 Filing: 000138713120002086 Input fundies:CapitalExpenditure: 61817 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/txmd-10k_123119.htm#1526030 Filing: 000138713120002086 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 132.62 million Exact value Exact value: -132617160 USD 2018-01-01 – 2018-12-31: -132617160 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2018-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -132617160 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -132617160 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm#1385706 Filing: 000138713121003140 The citation records this snapshot. The page link may show a newer release later.	−USD 106.81 million Exact value Exact value: -106811781 USD 2018-01-01 – 2018-12-31: -106811781 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2018-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -106811781 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -106811781 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm#1420821 Filing: 000138713121003140 The citation records this snapshot. The page link may show a newer release later.	USD 217,040 Exact value Exact value: 217040 USD 2018-01-01 – 2018-12-31: 217040 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2018-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 217040 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 217040 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm#1428494 Filing: 000138713121003140 The citation records this snapshot. The page link may show a newer release later.	−USD 107.03 million Calculation and evidence -106811781 − 217040 USD Exact free cash flow: -107028821 USD 2018-01-01 – 2018-12-31: -106811781 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 217040 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2018-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -107028821 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -106811781 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm#1420821 Filing: 000138713121003140 Input fundies:CapitalExpenditure: 217040 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm#1428494 Filing: 000138713121003140 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 176.15 million Exact value Exact value: -176145000 USD 2019-01-01 – 2019-12-31: -176145000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2019-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -176145000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -176145000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#3806582 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.	−USD 165.72 million Exact value Exact value: -165718000 USD 2019-01-01 – 2019-12-31: -165718000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2019-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -165718000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -165718000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2160281 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.	USD 2.45 million Exact value Exact value: 2450000 USD 2019-01-01 – 2019-12-31: 2450000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2019-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 2450000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2450000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2183667 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.	−USD 168.17 million Calculation and evidence -165718000 − 2450000 USD Exact free cash flow: -168168000 USD 2019-01-01 – 2019-12-31: -165718000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2450000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2019-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -168168000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -165718000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2160281 Filing: 000156459022011525 Input fundies:CapitalExpenditure: 2450000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2183667 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 183.52 million Exact value Exact value: -183524000 USD 2020-01-01 – 2020-12-31: -183524000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2020-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -183524000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -183524000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#3804682 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.	−USD 159.47 million Exact value Exact value: -159471000 USD 2020-01-01 – 2020-12-31: -159471000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2020-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -159471000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -159471000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2158167 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.	USD 207,000 Exact value Exact value: 207000 USD 2020-01-01 – 2020-12-31: 207000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2020-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 207000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 207000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2181725 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.	−USD 159.68 million Calculation and evidence -159471000 − 207000 USD Exact free cash flow: -159678000 USD 2020-01-01 – 2020-12-31: -159471000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 207000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2020-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -159678000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -159471000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2158167 Filing: 000156459022011525 Input fundies:CapitalExpenditure: 207000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-10k_20211231.htm#2181725 Filing: 000156459022011525 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 172.42 million Exact value Exact value: -172415000 USD 2021-01-01 – 2021-12-31: -172415000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2021-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -172415000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -172415000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-10k_20221231.htm#3452528 Filing: 000156459023005514 The citation records this snapshot. The page link may show a newer release later.	−USD 55.13 million Exact value Exact value: -55133000 USD 2021-01-01 – 2021-12-31: -55133000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2021-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -55133000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55133000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-10k_20221231.htm#1755262 Filing: 000156459023005514 The citation records this snapshot. The page link may show a newer release later.	USD 34,000 Exact value Exact value: 34000 USD 2021-01-01 – 2021-12-31: 34000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TherapeuticsMD, Inc. · 2021-12-31 TherapeuticsMD, Inc. (edgar:25743) Capital Expenditure: 34000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 34000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-10k_20221231.htm#1767197 Filing: 000156459023005514 The citation records this snapshot. The page link may show a newer release later.	−USD 55.17 million Calculation and evidence -55133000 − 34000 USD Exact free cash flow: -55167000 USD 2021-01-01 – 2021-12-31: -55133000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 34000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TherapeuticsMD, Inc. · 2021-12-31 TherapeuticsMD, Inc. (edgar:25743) Free cash flow: -55167000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55133000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-10k_20221231.htm#1755262 Filing: 000156459023005514 Input fundies:CapitalExpenditure: 34000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-10k_20221231.htm#1767197 Filing: 000156459023005514 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 112 million Exact value Exact value: 111997000 USD 2022-01-01 – 2022-12-31: 111997000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2022-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: 111997000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 111997000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea0201465-10k_therapeu.htm#1064347 Filing: 000121390024028003 The citation records this snapshot. The page link may show a newer release later.	USD 9.36 million Exact value Exact value: 9359000 USD 2022-01-01 – 2022-12-31: 9359000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2022-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: 9359000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9359000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea0201465-10k_therapeu.htm#686788 Filing: 000121390024028003 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 10.28 million Exact value Exact value: -10278000 USD 2023-01-01 – 2023-12-31: -10278000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2023-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -10278000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10278000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/ea0232034-10k_therapeu.htm#1244248 Filing: 000101376225003442 The citation records this snapshot. The page link may show a newer release later.	−USD 23.08 million Exact value Exact value: -23081000 USD 2023-01-01 – 2023-12-31: -23081000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2023-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: -23081000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23081000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000101376225003442/ea0232034-10k_therapeu.htm#827527 Filing: 000101376225003442 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 2.18 million Exact value Exact value: -2181000 USD 2024-01-01 – 2024-12-31: -2181000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TherapeuticsMD, Inc. · 2024-12-31 TherapeuticsMD, Inc. (edgar:25743) Net Income: -2181000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2181000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/ea0275992-10ka1_therap.htm#1160078 Filing: 000121390026037918 The citation records this snapshot. The page link may show a newer release later.	USD 1.17 million Exact value Exact value: 1170000 USD 2024-01-01 – 2024-12-31: 1170000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TherapeuticsMD, Inc. · 2024-12-31 TherapeuticsMD, Inc. (edgar:25743) Operating Cash Flow: 1170000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:15:00Z Snapshot: fdb619133d780779219397ccc396c5e8451b84cab7df5b0c724b5be11bb52724 Dimensions: Consolidated View: https://fundies.io/companies/edgar/25743/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1170000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/ea0275992-10ka1_therap.htm#831445 Filing: 000121390026037918 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

164 filings · 4,191 latest values · 4,191 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000025743, 25743, TXMD, edgar:25743

Also known as AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO, THERAPEUTICSMD, INC., TherapeuticsMD, Inc.

TherapeuticsMD, Inc.

Latest quarter

Revenue

Operating cash flow

Trailing twelve months

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation